✦ LIBER ✦

Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab

✍ Scribed by Robert S. Wallis; Stefan Ehlers

Book ID: 113899682
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 133 KB
Volume: 34
Category: Article
ISSN: 0049-0172
DOI: 10.1016/j.semarthrit.2005.01.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differential effects of the tumor necros

Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro

✍ Firas Thaher; Sandra Plankenhorn; Reinhild Klein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 387 KB

Tumor necrosis factor blockade and the r

Tumor necrosis factor blockade and the risk of viral infection

✍ Kim, Seo Young; Solomon, Daniel H. 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 274 KB

A comprehensive review and evaluation of

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

✍ Scheinfeld, N 📂 Article 📅 2004 🏛 Informa plc 🌐 English ⚖ 413 KB

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of JC virus infection

✍ Jonathan C. P. Roos; Andrew J. K. Ostor 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

Decreased incidence of anterior uveitis

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept

✍ J. Braun; X. Baraliakos; J. Listing; J. Sieper 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Abstract ## Objective To estimate the incidence of anterior uveitis in patients with ankylosing spondylitis (AS) who underwent anti–tumor necrosis factor (anti‐TNF) therapy, using data from recently performed trials. ## Methods Data from 4 placebo‐controlled studies with anti‐TNF agents in AS

Tumor Necrosis Factor Antagonists: Diffe

Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection

✍ Daniel E. Furst; Robert Wallis; Michael Broder; David O. Beenhouwer 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 383 KB